PHARMASEAL establishes an Advisory Board
As we start 2024, I am thrilled to announce our new advisory board has been created and I look forward to working closely with the following esteemed members:
John Young who I first met at University of Glasgow in early 1980’s and then again some 35 years later! John has had an impressive career with Pfizer in a number of pivotal roles worldwide and finally as a group president reporting to the CEO. John now serves as an active board member with a number of companies. I recently had the good fortune of spending some time with John at a university reunion in the summer of 2023.
Wayne Kubick serving as the CTO of Parexel hired me way back in 1991 in their first UK IT role, in a newly acquired business in Ealing, London (which also happened to be their first European acquisition). This job also derailed my planned emigration to Vancouver. Wayne is well connected in the industry from being part of a number of US startups with successful exits, and also having served as the CTO of CDIS and HL7.
Karen Roy has been instrumental in the formation of global #etmf standards, leading this initiative for over a decade, culminating in 3 major versions of these standards. The etmf model has been implemented by several software vendors and adopted by numerous companies worldwide. Karen is busy now transitioning these standards across to CDSIC and continuing to provide leadership, whilst also rejoining the board of the Institute of Clinical Research.
I am excited to welcome advisors of such high calibre to our team, ones that I am lucky enough to call friends first. With their combined counsel, I have no doubt that we will achieve great things and continue to develop
PHARMASEAL and our clinical trial management platform Engility®.